Spanish researchers have created a powerful new open-source tool that helps uncover the hidden genetic networks driving ...

Corsera Health Inc. has filed a clinical trial notification (CTN) seeking to initiate a phase I trial of COR-1004 in New Zealand. COR-1004 is a novel investigational subcutaneously administered siRNA ...

Advancing a once-annual preventive RNAi medicine designed to reduce the two key drivers of cardiovascular disease: LDL-C and blood pressure Filed application for COR-1004, a novel siRNA targeting ...

Corsera Health, Inc., leading the future of cardiovascular health through prediction and prevention, today announced the filing of a clinical trial notification (CTN) to initiate a Phase 1 clinical ...

Meghana Keshavan covers biotech and contributes to The Readout newsletter. Get your daily dose of health and medicine every weekday with STAT’s free newsletter Morning Rounds. Sign up here. Morning, ...

Adam Feuerstein is a senior writer and biotech columnist, reporting on the crossroads of drug development, business, Wall Street, and biotechnology. He is also a co-host of the weekly biotech podcast ...

Two biotech leaders, John Maraganore and Clive Meanwell, are embarking on what Maraganore is calling their third act together: a new start-up called Corsera Health. Their first act together, as ...

Salesloft said a breach of its GitHub account in March allowed hackers to steal authentication tokens that were later used in a mass-hack targeting several of its Big Tech customers. Citing an ...

– Late-breaking presentation at ESC Congress 2025 confirms that early, persistent lowering of LDL-C and blood pressure leads to improved cardiovascular health outcomes – – Raised over $50 million to ...

Corsera Health, Inc. announced its launch today with a mission to extend healthspan through cardiovascular disease prediction and prevention. The company will shape the future of cardiovascular health ...

To continue reading this content, please enable JavaScript in your browser settings and refresh this page. Preview this article 1 min The Boston startup is developing ...